| Risk medication |
|
|
| Medication increasing risk of falls |
1 |
Focus on medication increasing the risk of falls
results in a significant reduction in thenumber of drugs, but no
change in the number of falls |
| Heart medication |
1 |
No effect on clinical outcomes |
| Anticoagulant medication |
2 |
A significant reduction in likelihood of hospital
admission |
| Blood pressure lowering medication |
2 |
A significant improvement in blood pressure
together with an economic advantage |
| Antidiabetic medication |
3 |
A significant improvement of HbA1c and adherence.
Economic outcomes were notmeasured. |
| Medication for Parkinson’s Disease |
2 |
A significant reduction in non-motor function
related symptoms. Quality of life wasimproved. |
| Risk patients |
|
|
| Frail patients |
7 |
Overall increased deprescribing and improved
adherence. Significant economicadvantage for frail,
home-dwelling patients. |
| Patients recently discharged from hospital |
3 |
A significant reduction in the number of
readmissions to hospital and the number ofdeaths |
| Patients with multimorbidity |
7 |
An overall reduction in hospital admissions, visits
to accident & emergency departmentsand improved
adherence. A significant economic advantage. |
